---
title: "Daiwa Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295911072.md"
description: "Daiwa reaffirmed its Buy rating on BeOne Medicines Ltd (6160) with a HK$270.00 price target in an August 12 report, noting the stock closed at HK$216.60. The analyst consensus remains a Strong Buy with an average target of HK$271.41, implying 25.30% upside. Bank of America Securities also maintained a Buy rating on August 6 with a HK$255.43 target."
datetime: "2026-08-14T09:15:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295911072.md)
  - [en](https://longbridge.com/en/news/295911072.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295911072.md)
generator: "portal-rs"
---

# Daiwa Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

In a report released on August 12, from Daiwa maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$270.00. The company’s shares closed today at HK$216.60.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Currently, the analyst consensus on BeOne Medicines Ltd is a Strong Buy with an average price target of HK$271.41, implying a 25.30% upside from current levels. In a report released on August 6, Bank of America Securities also maintained a Buy rating on the stock with a HK$255.43 price target.

### Related Stocks

- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)
- [8601.JP](https://longbridge.com/en/quote/8601.JP.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [BeOne Medicines and partners renew Brukinsa access programme for CLL](https://longbridge.com/en/news/296331290.md)
- [Bank of China Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)](https://longbridge.com/en/news/285667787.md)
- [Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/296029142.md)
- [BeOne Medicines Ltd (6160) Gets a Buy from CMBC International](https://longbridge.com/en/news/285886964.md)
- [REG - BlackRock Group Gamma Communications - Form 8.3 - Gamma Communications plc](https://longbridge.com/en/news/296369572.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**